2019冠状病毒病疫苗：修订间差异

维基百科，自由的百科全书
以互动方式浏览历史
←上一版本下一版本→
删除的内容 添加的内容
可视化wikitext
→‎top：​ 改善已翻译部分的语句，顺便感谢Formuse所做的相关外链
第7行： 第7行：


==2020年针对疫情的尝试==
==2020年针对疫情的尝试==
SARS-CoV-2 was identified on 1 December 2019 as the cause of what would later be named COVID-19.[14] A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.[14][15] Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.[14][16][17][18] About 35 companies and academic institutions are involved,[19] with three of them receiving support from the Coalition for Epidemic Preparedness Innovations (CEPI), including projects by the biotechnology companies Moderna,[20] and Inovio Pharmaceuticals, and the University of Queensland.[21] Some 300 early-stage studies are in progress worldwide, according to one report on 10 March 2020.[22]
SARS-CoV-2 发现于2019年12月1日，其后续引发的疾病被命名为COVID-19<ref name="Fauci">{{cite journal | last=Fauci | first=Anthony S. | last2=Lane | first2=H. Clifford | last3=Redfield | first3=Robert R. | title=Covid-19 — Navigating the Uncharted | journal=New England Journal of Medicine | date=28 February 2020 | issn=0028-4793 | doi=10.1056/nejme2002387| pmid=32109011 }}</ref> A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.[14][15] Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.[16][17][18] About 35 companies and academic institutions are involved,[19] with three of them receiving support from the Coalition for Epidemic Preparedness Innovations (CEPI), including projects by the biotechnology companies Moderna,[20] and Inovio Pharmaceuticals, and the University of Queensland.[21] Some 300 early-stage studies are in progress worldwide, according to one report on 10 March 2020.[22]


In early March 2020, CEPI announced a US$2 billion funding goal in a global partnership between public, private, philanthropic, and civil society organisations to accelerate development of COVID-19 vaccines, with commitments to date by the governments of Denmark, Finland, Germany, Norway, and the UK.[23]
In early March 2020, CEPI announced a US$2 billion funding goal in a global partnership between public, private, philanthropic, and civil society organisations to accelerate development of COVID-19 vaccines, with commitments to date by the governments of Denmark, Finland, Germany, Norway, and the UK.[23]

2020年3月24日 (二) 08:13的版本

2019冠状病毒病疫苗是一个尚处于实验阶段用于对抗2019冠状病毒病疫情的疫苗。虽然目前没有通过实际临床实验，但仍然有多次尝试开发此疫苗。2020年2月世界卫生组织表示他们不期待在未来18个月内能有任何可用的疫苗出现。截至2020年3月，已经有30余种候选疫苗正在研发。

早先对于类似病毒的尝试

早先已经有多种疫苗被研发用于针对各种冠状病毒，其中包括禽类支气管冠状病毒、犬冠状病毒以及猫冠状病毒[1]。而针对SARS[2]以及MERS[3]的疫苗也进行过动物实验，可截至2020年仍然没有可安全有效的应用于人类身上的疫苗出现[4]。根據2005年至2006年發表的論文，開發用於治療SARS的新型疫苗和藥物是全球政府和公共衛生機構的當務之急。

並沒有針對MERS驗證有效的疫苗。當MERS盛行時，人們認為現有的SARS研究可能為開發針對MERS病毒感染的疫苗和療法提供有用的樣板。 到2020年3月，有一種（基於DNA）MERS疫苗已完成了人類的I期臨床試驗，还有3种病毒载体疫苗处于研发之中其中包括两个腺病毒载体 (ChAdOx1-MERS, BVRS-GamVac),和一个以改良牛痘（Modified vaccinia Ankara）为载体的 (MVA-MERS-S).[5]

2020年针对疫情的尝试

SARS-CoV-2 发现于2019年12月1日，其后续引发的疾病被命名为COVID-19[6] A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.[14][15] Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.[16][17][18] About 35 companies and academic institutions are involved,[19] with three of them receiving support from the Coalition for Epidemic Preparedness Innovations (CEPI), including projects by the biotechnology companies Moderna,[20] and Inovio Pharmaceuticals, and the University of Queensland.[21] Some 300 early-stage studies are in progress worldwide, according to one report on 10 March 2020.[22]

In early March 2020, CEPI announced a US$2 billion funding goal in a global partnership between public, private, philanthropic, and civil society organisations to accelerate development of COVID-19 vaccines, with commitments to date by the governments of Denmark, Finland, Germany, Norway, and the UK.[23]

參考資料

  1. ^ Cavanagh, Dave. Severe acute respiratory syndrome vaccine development: Experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathology. 2003, 32 (6): 567–582. PMID 14676007. doi:10.1080/03079450310001621198. 
  2. ^ Gao, Wentao; Tamin, Azaibi; Soloff, Adam; d'Aiuto, Leonardo; Nwanegbo, Edward; Robbins, Paul D.; Bellini, William J.; Barratt-Boyes, Simon; Gambotto, Andrea. Effects of a SARS-associated coronavirus vaccine in monkeys. The Lancet. 2003, 362 (9399): 1895–1896. PMID 14667748. doi:10.1016/S0140-6736(03)14962-8. 
  3. ^ Kim, Eun; Okada, Kaori; Kenniston, Tom; Raj, V. Stalin; Alhajri, Mohd M.; Farag, Elmoubasher A.B.A.; Alhajri, Farhoud; Osterhaus, Albert D.M.E.; Haagmans, Bart L.; Gambotto, Andrea. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/C mice. Vaccine. 2014, 32 (45): 5975–5982. PMID 25192975. doi:10.1016/j.vaccine.2014.08.058. 
  4. ^ https://doi.org/10.2217%2Ffvl.12.126
  5. ^ Yong, Chean Yeah; Ong, Hui Kian; Yeap, Swee Keong; Ho, Kok Lian; Tan, Wen Siang. Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Frontiers in Microbiology. 2019, 10: 1781. PMC 6688523 可免费查阅. PMID 31428074. doi:10.3389/fmicb.2019.01781. 
  6. ^ Fauci, Anthony S.; Lane, H. Clifford; Redfield, Robert R. Covid-19 — Navigating the Uncharted. New England Journal of Medicine. 28 February 2020. ISSN 0028-4793. PMID 32109011. doi:10.1056/nejme2002387. 
取自“https://zh.wikipedia.org/w/index.php?title=2019冠状病毒病疫苗&oldid=58782048”